Chordia Therapeutics Inc. (190A) Press Release
Announcement of Orphan Drug Designation in Japan for rogocekib for Relapsed or Refractory AML
Earlier from Chordia Therapeutics
- Announcement Regarding the Review Status of Orphan Drug Designation for Rogocekib, a CLK Inhibitor
- Notice of Receipt of Grant
- Non-consolidated Financial Results for the Nine Months Ended May 31 2026 [Japanese GAAP]
- TABLE-Chordia Therapeutics - 6-MTH parent results